A Phase 1 Study of the Safety and Pharmacokinetics of XMT-1107 Administered as an Intravenous Infusion Once Every Three Weeks to Patients With Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 27 Sep 2016
At a glance
- Drugs XMT 1107 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Mersana Therapeutics
- 16 May 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 03 Apr 2013 Planned end date changed from 1 Jan 2013 to 1 Sep 2013 as reported by ClinicalTrials.gov.
- 30 Jul 2012 Additional trial centre and investigator identified as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History